Hanmi Inks Record Korean Deal, With Boehringer For Cancer Therapy
This article was originally published in PharmAsia News
Executive Summary
Hanmi Pharmaceutical continues to lead South Korean pharma innovators by reaching a series of major licensing out deals. Following the major agreement with Lilly for its oral Bruton's tyrosine kinase inhibitor earlier this year, Hanmi has now inked an even bigger license agreement with Boehringer Ingelheim, for a novel non-small cell lung cancer therapy HM61713 that will beef up the German firm's oncology portfolio.